Fibrous lung tissue lesions: treatment opportunities for post-COVID-19 patients

Abstract

The article presents the analysis of scientific databases eLIBRARY, PubMed, Scopus on the topic of COVID-19 adverse outcomes and the treatment methods for their prevention. The post-COVID-19 syndrome is a pathological condition that includes persistent physical, medical and cognitive consequences of a new coronavirus disease, including persistent immunosuppression, as well as fibrosis of the lungs, heart and blood vessels. The morphological basis of acute respiratory distress syndrome in COVID-19 is severe diffuse alveolar damage characterized by hypoxemia, bilateral pulmonary infiltrates, and decreased lung compliance. A promising domestic drug, the use of which can reduce the risk of developing irreversible fibrotic changes in the lung tissue, is Longidaza.

Keywords

• covid-19
• pulmonary fibrosis
• longidaza
• treatment
• ards